β-Aminopropionitrile (BAPN) is a specific, irreversible and orally active lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes[2].In Vitro: β-Aminopropionitrile (BAPN) normalizes the expression of GLUT4 and adiponectin, and improves glucose uptake in an in vitro model of insulin resistance.
β-Aminopropionitrile (500 μM; 72 h) blocks the hypoxia-induced EMT morphological and marker protein changes, and inhibits invasion and migration capacities of cervical carcinoma cells in vitro[2].In Vivo: β-Aminopropionitrile (BAPN) (100 mg/kg/day; p.o.; 6 weeks) reduces body weight gain and improves the metabolic profile in diet-induced obesity in rats.
β-Aminopropionitrile monofumarate (1 g/kg/day; p.o.; 4 weeks) induces thoracic aortic dissection in C57BL/6 mice.